Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Change in Receivables (2022 - 2025)

Mirum Pharmaceuticals has reported Change in Receivables over the past 4 years, most recently at $19.0 million for Q4 2025.

  • Quarterly results put Change in Receivables at $19.0 million for Q4 2025, up 74.96% from a year ago — trailing twelve months through Dec 2025 was $48.1 million (up 320.58% YoY), and the annual figure for FY2025 was $48.1 million, up 320.58%.
  • Change in Receivables for Q4 2025 was $19.0 million at Mirum Pharmaceuticals, up from $3.1 million in the prior quarter.
  • Over the last five years, Change in Receivables for MIRM hit a ceiling of $20.1 million in Q4 2023 and a floor of -$13.0 million in Q1 2024.
  • Median Change in Receivables over the past 4 years was $7.9 million (2022), compared with a mean of $7.8 million.
  • Biggest five-year swings in Change in Receivables: soared 432.94% in 2023 and later crashed 2044.38% in 2024.
  • Mirum Pharmaceuticals' Change in Receivables stood at $7.7 million in 2022, then skyrocketed by 162.95% to $20.1 million in 2023, then tumbled by 46.04% to $10.9 million in 2024, then soared by 74.96% to $19.0 million in 2025.
  • The last three reported values for Change in Receivables were $19.0 million (Q4 2025), $3.1 million (Q3 2025), and $9.1 million (Q2 2025) per Business Quant data.